Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics

Wall Street analysts project Regeneron (REGN) to report a significant Q2 earnings per share decline of 30.5% year-over-year to $8.03, alongside a 5.7% revenue decrease to $3.34 billion, with consensus EPS estimates recently revised down by 6.5%. This revenue contraction is largely attributed to an anticipated 33% drop in US Eylea sales, despite strong projected growth from Dupixent and overall collaboration revenues. While the company carries a Zacks #4 (Sell) rank, REGN shares have recently outperformed the broader market.

Analysis

Wall Street analysts anticipate a significant contraction for Regeneron in its upcoming Q2 results, with consensus estimates pointing to a 30.5% year-over-year decline in earnings per share to $8.03 and a 5.7% drop in total revenues to $3.34 billion. This bearish outlook is underscored by a recent 6.5% downward revision to the consensus EPS estimate over the past 30 days. The primary driver for this projected decline is a severe drop in US sales for the company's key drug, Eylea, which are forecast to fall 33% to $1.03 billion, causing overall net product sales to decrease by an estimated 23.9%. However, this weakness is partially offset by continued strength in collaboration revenues, which are expected to grow 13.7%, and robust performance from other key products. Notably, Dupixent sales are projected to grow strongly, with US sales up 16.7% and ROW sales up 22.7%, while Libtayo and Evkeeza are also expected to post double-digit growth. Despite these negative headline forecasts and a Zacks Rank #4 (Sell), REGN shares have outperformed the S&P 500 over the past month (+6.4% vs +3.6%), indicating a potential disconnect between recent stock performance and underlying analyst expectations.

Key Decisions for Investors

• Investors should focus on the magnitude of the Eylea sales decline versus the growth in Dupixent and collaboration revenues, as the key question is whether strength in growth assets can offset the flagship product's weakness and beat the lowered consensus bar.
• Given the stock's recent outperformance against a backdrop of negative estimate revisions and a 'Sell' rating, the position may be vulnerable to a significant correction if the company fails to meet or provide an optimistic outlook.
• Consider the mixed signals as a potential volatility event; any management commentary on the competitive pressures impacting Eylea will be critical for assessing if the current challenges are temporary or indicative of a longer-term structural shift in the portfolio's revenue mix.